Live Breaking News & Updates on Swiss Stock Exchange Novn

Stay updated with breaking news from Swiss stock exchange novn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Novartis and Medicines for Malaria Venture announce

There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem® (artemether-. ....

United States , Burkina Faso , Sloan Simpson , Parag Mahanti , Nicole Zinsli Somm , Michael Meo , Jonathan Graham , Isabella Zinck , Marlena Abdinoor , Richard Jarvis , Satoshi Sugimoto , Imke Kappes , Exchange Commission , European Developing Countries Clinical Trials Partnership , Multilateral Initiative On Malaria , Malaria Venture , Multilateral Initiative , Pan African Malaria Conference , Chief Medical Officer , Developing Countries Clinical Trials Partnership , Coartem About , New Artemether Lumefantrine Dispersible Tablet , Neonates Plasmodium , Swiss Stock Exchange Novn , Novartis Pharma Ag , Media Release ,

Novartis radioligand therapy Lutathera® FDA approved as

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17). ....

United States , Baja California , Isabella Zinck , Theodore Laetsch , Michael Meo , Tina Deignan , Marlena Abdinoor , Nicole Zinsli Somm , Richard Jarvis , Satoshi Sugimoto , Parag Mahanti , Sloan Simpson , Jonathan Graham , Imke Kappes , Exchange Commission , Developmental Therapeutics Program , Elsevier Inc , Drug Administration , Therapeutic Area Head , Radioligand Therapy , Metab Clin North , Survival Outcomes , Patients With Neuroendocrine Tumors , Related Cancer , Gastroenteropancreatic Neuroendocrine , Evaluate Safety ,

New Novartis data show early addition of twice-yearly*

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal. ....

United States , South Korea , Noord Holland , Jonathan Graham , Richard Jarvis , Isabella Zinck , Satoshi Sugimoto , Nicole Zinsli Somm , Coll Cardiol , Parag Mahanti , Michael Meo , Imke Kappes , Michael Koren , Marlena Abdinoor , Sloan Simpson , American Heart Association , Novartis Pharmaceuticals Corp , American College Of Cardiology Congress , Alnylam Pharmaceuticals , European Society Of Cardiology Congress , World Health Organization , European Union , Jacksonville Center , Journal Of The American College Cardiology , Exchange Commission , European Medicines Agency ,

Novartis Scemblix® shows superior major molecular response

MEDIA & INVESTOR RELEASE Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for. ....

United States , Michael Meo , Zain Iqbal , Richard Jarvis , Satoshi Sugimoto , Parag Mahanti , Jonathan Graham , Imke Kappes , Isabella Zinck , Sloan Simpson , Marlena Abdinoor , Julie Masow , Novartis Scemblix , Shreeram Aradhye , Samir Shah , Tim Hughes , Nicole Zinsli Somm , Dmax Foundation , Exchange Commission , Australian Health Medical Research Institute , Leukemia Research , South Australian Health , Medical Research Institute , Chief Medical Officer , Novartis Commitment , Term Outcomes ,

Novartis upgrades mid-term sales growth guidance, showcases

Ad hoc announcement pursuant to Art. 53 LR ‘Pure-play’ innovative medicines strategy focused on four therapeutic areas and five technology platforms,. ....

City Of , United Kingdom , United States , Richard Jarvis , Isabella Zinck , Samir Shah , Sloan Simpson , Julie Masow , Parag Mahanti , Satoshi Sugimoto , Michael Meo , Imke Kappes , Marlena Abdinoor , Zain Iqbal , Nicole Zinsli Somm , Jonathan Graham , Exchange Commission , Biomedical Research , Global Health , Cell Therapy , Therapeutic Areas , Spinal Muscular Atrophy , Spontaneous Urticaria , Inducible Urticaria , Muscular Atrophy , Castration Resistant Prostate Cancer ,